Trpv1tm1jul

Female Sprague-Dawley rats with male pups were obtained from Envigo (Frederick, MD) when the litters were P7 (except for NMDA-evoked spasms). For experiments in P20 mice, heterozygous TRPV1-null mice (Trpv1^tm1Jul, Jackson Laboratories, Stock #003770, Bar Harbor, ME) (Caterina et al., 2000 (link)) were bred and both male and female wildtype and TRPV1-null littermate mice were used for seizure testing. Two age groups were used for seizure testing: P10 and P20; these ages were selected model infancy and pre-adolescence in humans, respectively (Dobbing and Sands, 1979 (link)). At P10 or P20, pups were weighed, numbered, and randomly assigned to a treatment group. The pups were pretreated with CBDV (50, 100, or 200 mg/kg) or vehicle and returned to their dam for 60 min before seizure testing. During the observation period, pups were not subjected to any passive or active heating.
Synthetic CBDV (Cayman Chemical, Ann Arbor, MI) was prepared in a 2:1:17 ratio of ethanol:Kolliphor:0.9% saline (Sigma-Aldrich, St. Louis, MO), which also served as the corresponding vehicle solution. Drug was dissolved at concentrations of 5, 10, or 20 mg/mL and administered intraperitoneally (ip) at a volume of 10 mL/kg of body weight to deliver 50, 100 or 200 mg/kg of drug. These doses of CBDV are effective in adult models of epilepsy (Hill et al., 2012 (link), 2013 (link)).